

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SANDOZ, INC.,
Petitioner,

v.

GENENTECH, INC.,
Patent Owner.

Case IPR2017-02042
Patent 7,976,838 B2

Before ERICA A. FRANKLIN, SHERIDAN K. SNEDDEN and
JACQUELINE T. HARLOW, *Administrative Patent Judges*.

FRANKLIN, *Administrative Patent Judge*.

DECISION
Denying Institution of *Inter Partes* Review
37 C.F.R. § 42.108

I. INTRODUCTION

Sandoz, Inc. (“Petitioner”) filed a Petition (Paper 1; “Pet.”) to institute an *inter partes* review of claims 1–14 of US 7,976,838 B2 (Ex. 1001; “the ’838 patent”). Genentech, Inc. (“Patent Owner”) filed a Patent Owner Preliminary Response. Paper 8 (“Prelim. Resp.”). Petitioner filed an authorized Reply to the Patent Owner Preliminary Response.¹ Paper 10.

We have jurisdiction under 35 U.S.C. § 314, which provides that an *inter partes* review may not be instituted “unless . . . there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a).

Upon consideration of the Petition and Preliminary Response, we determine that the Petition raises the same or substantially the same prior art and arguments previously presented and considered by the Office. Consequently, we exercise our discretion under § 325(d) and *deny* the Petition.

A. *Related Proceedings*

The parties inform us that two other petitions were filed about the same time as the Petition in the instant proceeding, each concerning the ’838 patent: IPR2017-01923 (petitioner Pfizer, Inc.) and IPR2017-02036 (petitioner Sandoz, Inc.). Pet. 4; Paper 4, 2. Previously, claims of the ’838 patent were challenged in IPR2015-00417 (petitioner Boehringer Ingelheim

¹ We authorized the Reply only to address factors considered by the Board when evaluating whether to exercise discretion under § 314(a), in view of the recent designation of *General Plastic Industrial Co., Ltd. v. Canon Kabushiki Kaisha*, Case IPR2016-01357, Paper 19 (September 6, 2017) as precedential. Paper 9.

Int'l GmbH). After institution, the case was terminated upon a request by petitioner Boehringer. Case IPR2015-00417, Papers 11, 18. Prior to that termination, another petition challenging claims of the '838 patent was filed in IPR2015-01733 (petitioner Celltrion, Inc.), along with a motion for joinder with IPR2015-00417. Case IPR2015-01733, Papers 2, 3.

Subsequently, the petition was dismissed upon a request by Celltrion, Inc. *Id.*, Paper 12. Thereafter, Celltrion filed a petition in IPR2016-01667 that was denied on the merits. Case IPR2016-01667, Papers 2, 15.

B. The '838 patent

The '838 patent discloses methods of treating rheumatoid arthritis (“RA”) in a human patient who experiences an inadequate response to a TNF α -inhibitor. Ex. 1001, Abstract, 4:3–24. The Specification expressly defines the term “inadequate response to a TNF α -inhibitor” as follows:

[A]n inadequate response to previous or current treatment with a TNF α -inhibitor because of toxicity and/or inadequate efficacy. The inadequate response can be assessed by a clinician skilled in treating the disease in question.

Id. at 5:25–29. Commercial examples of TNF α -inhibitors include Etanercept (ENBREL[®]), Infliximab (REMICADE[®]) and Adalimumab (HUMIRA[™]). *Id.* at 5:19–24.

The methods of the claimed invention involve administering an antagonist that binds to a B cell surface marker, such as CD20. *Id.* at 4:60–65. The Specification discloses rituximab (RITUXAN[®]) as such an antagonist, explaining that it is “a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen.” *Id.* at 2:32–34.

C. Illustrative Claims

Claims 1, 2, 8, 10 and 11 are the independent claims challenged, and are reproduced below:

1. A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNF α -inhibitor, comprising administering to the patient an antibody that binds to CD20, wherein the antibody is administered as two intravenous doses of 1000 mg.

2. A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNF α -inhibitor, comprising administering to the patient an antibody which binds to CD20 in an amount that is effective to provide an ACR50 response at week 24, ACR70 response at week 24, or no erosive progression at weeks 24 and beyond, wherein the antibody is administered as two intravenous doses of 1000 mg.

8. A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNF α -inhibitor, comprising administering to the patient rituximab, wherein rituximab is administered as two intravenous doses of 1000 mg.

10. A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNF α -inhibitor, comprising administering to the patient rituximab, and methotrexate, wherein the patient has no erosive progression at weeks 24 and beyond, and wherein rituximab is administered as two intravenous doses of 1000 mg.

11. A method of achieving a clinical response selected from the group consisting of ACR50 response at week 24, ACR70 response at week 24, and no erosive progression at weeks 24 and beyond, in a human rheumatoid arthritis patient who experiences an inadequate response to a TNF α -inhibitor, comprising administering to the patient rituximab, and

methotrexate, wherein rituximab is administered as two intravenous doses of 1000 mg.

Claims 3–7 depend from claim 2, either directly or indirectly. Claim 9 depends directly from claim 8. Claims 12–14 depend directly from claim 11.

D. The Asserted Grounds of Unpatentability

Petitioner challenges the patentability of claims 1–14 of the '838 patent as obvious over Edwards 2002,² Patel,³ and Curd⁴; and over Edwards 2002, Tuscano,⁵ and Curd. Pet. 6. Petitioner also relies on the Declarations of David Fox, M.D., Ph.D. (Ex. 1107) and William J. Jusko, Ph.D. (Ex. 1108).

II. ANALYSIS

Discretionary Denial under 35 U.S.C. § 325(d)

Patent Owner asserts that we should exercise our discretion to deny the Petition under 35 U.S.C. § 325(d) because Petitioner's asserted grounds rely upon the same or substantially the same prior art previously considered by the Office, and Petitioner has not explained why such discretion should

² Edwards et al., *Efficacy and Safety of Rituximab, a B-Cell Targeted Chimeric Monoclonal Antibody: A Randomized, Placebo-Controlled Trial in Patients with Rheumatoid Arthritis*, 46 ARTHRITIS & RHEUM S197, 446 (2002). Ex. 1138.

³ Dhavalkumar Patel, *B Cell-Ablative Therapy for the Treatment of Autoimmune Diseases*, 46 ARTHRITIS & RHEUM 1984-85 (2002). Ex. 1159.

⁴ Patent Application Publication No. WO 00/67796 A1 by John G. Curd et al., published Nov. 16, 2000. Ex. 1116.

⁵ Joseph M. Tuscano, *Successful Treatment of Infliximab-Refractory Rheumatoid Arthritis with Rituximab*, 46 ARTHRITIS & RHEUM 3420, LB11 (2002). Ex. 1136.

not be exercised. Prelim. Resp. 11–20 (citing *Unified Patents, Inc. v. Berman*, IPR2016-01571, Paper 10 at 11–12 (Dec. 14, 2016) (informative). Patent Owner describes in detail how it perceives that the Petition relies on “identical (or at minimum substantially the same) prior art and arguments previously presented in both original prosecution and earlier IPRs (IPR2015-00417 by Boehringer; IPR2015-01733 and IPR2016-01667 by Celltrion).” *Id.*

According to Petitioner, “[t]he grounds, evidence, and/or arguments relied upon in th[e] Petition are different than what was relied upon in IPR2016-01667, IPR2015-01733, IPR2015-00417, and IPR2017-01923, and during the prosecution of the ’838 patent.” Pet. 4. To the extent that any such differences exist, Petitioner has not explained or even alleged that the prior art and the arguments presented in the Petition are not *substantially the same* as those considered and abandoned by the Examiner during prosecution, and as those presented and considered previously by the Board.

Institution of an *inter partes* review is discretionary. *See Harmonic Inc. v. Avid Tech., Inc.*, 815 F.3d 1356, 1367 (Fed. Cir. 2016) (explaining that under § 314(a), “the PTO is permitted, but never compelled, to institute an IPR proceeding”). Specifically, “the Board may authorize the review to proceed” or “deny some or all grounds for unpatentability for some or all of the challenged claims.” 37 C.F.R. § 42.108(a), (b). An example of this discretion may be applied with respect to the occurrence of multiple petitions challenging the same patent, as set forth in 35 U.S.C. § 325(d), which states, in relevant part:

(d) MULTIPLE PROCEEDINGS -- . . . In determining whether to institute or order a proceeding under this chapter, chapter 30, or chapter 31, the Director may take into account whether, and reject the petition or request because, the same or substantially the same prior art or arguments previously were presented to the Office.

35 U.S.C. § 325(d).

After considering the arguments and evidence, and for the reasons set forth in the following discussion, we agree with Patent Owner that Petitioner’s asserted combination of Edwards 2002, Curd, and Patel or Tuscano raises the same or substantially the same prior art and arguments previously presented and considered by the Office. Consequently, we exercise our discretion under § 325(d) and deny the Petition.

In seeking denial of the Petition based upon prior art and arguments previously presented to the Board, Patent Owner focuses on IPR2016-01667. Prelim. Resp. 16–20. In considering whether to exercise our discretion under § 325(d), we focus on IPR2016-01667 also, and refer to it as the “Celltrion proceeding.”

The Celltrion proceeding represents the third challenge to claims of the ’838 patent. In that proceeding, Celltrion presented three grounds challenging claims of the ’838 patent, wherein one ground challenged claims 1–14 as obvious over the combination of Edwards 2002 and Tuscano, and another ground challenged those claims as obvious over Goldenberg, Curd, and DeVita 2001⁶. IPR2016-01667, Paper 2.

⁶De Vita et al., *Pathogenic Role of B Lymphocytes in Rheumatoid Synovitis: B Cell Selective Blocking Can Induce a Clinical Response in Patients with Refractory Rheumatoid Arthritis*, REUMATISMO, Vol. 53, No. 3 (Suppl. No. 4) (2001) [ENGLISH TRANSLATION]. IPR2016-01667, Ex. 1005.

Regarding the combination of Edwards 2002 and Tuscano, Celltrion asserted that Edwards 2002 discloses every limitation of the challenged independent claims, including administering two intravenous doses of 1000 mg of rituximab, and, allegedly treating a patient who experiences an inadequate response to a TNF α -inhibitor. IPR2016-01667, Paper 2 at 46. In the combination, Celltrion relied on Tuscano as *expressly* disclosing treating a patient with rituximab when they have experienced an inadequate response to a TNF α -inhibitor with rituximab. *Id.* According to Celltrion, a person of skill in the art would have been motivated to administer rituximab according to the regimen disclosed in Edwards 2002 to the inadequate responders of TNF α -inhibitor in Tuscano with a reasonable expectation of success “because Edwards 2002 disclosed that the regimen is an effective therapy for RA.” *Id.* Celltrion acknowledged that Tuscano used a higher total dose of rituximab than Edwards 2002 and asserted “the claimed doses are obvious, as the lower doses were successfully used in Edwards 2002.” *Id.* at 48.

Additionally, Celltrion asserted that a skilled artisan would have had a reasonable expectation of success using the Edwards 2002 dosing with Tuscano’s patients based upon “[o]ther studies, which report using about 2000 mg total dose of rituximab to treat RA successfully.” *Id.* Further, Celltrion asserted “there is nothing critical about the claimed total dose of 2000 mg.” *Id.* According to Celltrion, “it would have been a matter of routine optimization for a POSA . . . to adjust the doses of rituximab to achieve the desired clinical outcome.” *Id.* at 49.

Regarding the combination Goldenberg, Curd, and De Vita 2001, Celltrion asserted that Goldenberg and De Vita 2001 each teach treating a patient who experiences an inadequate response to a TNF α -inhibitor with rituximab. IPR2016-01667, Paper 2 at 51. Celltrion asserted also that Goldenberg and Curd each teach combining methotrexate with rituximab therapy. *Id.*

Celltrion did not allege that Goldenberg, Curd, or De Vita 2001 teaches the claimed dosage of rituximab, i.e., two intravenous doses of 1000 mg. *Id.* at 52. Rather, according to Celltrion, a person of ordinary skill in the art “would have been motivated to optimize the dose of rituximab used to treat RA.” *Id.* at 53. In support of that contention, Celltrion asserted that the total dosage administered in the claimed methods, i.e., 2000 mg, falls squarely between the successful total dose of 1500 mg disclosed in Goldenberg and the successful total dose of 2550 mg disclosed in De Vita 2001. *Id.* Further, Celltrion asserted that a person of skill would have been motivated to administer rituximab in as few doses as possible to increase patient compliance and convenience. *Id.* at 53. Celltrion asserted also that Curd would have motivated the skilled artisan optimize the selection of an appropriate dose and schedule. *Id.*

In the instant Petition, Petitioner argues both of its asserted grounds together, referring to a combined obviousness challenge based upon “Edwards 2002 in view of Patel or Tuscano and Curd.” Pet. 32. In doing so, Petitioner relies on Edwards 2002 and Curd in substantially the same manner set forth in Celltrion’s petition. For example, Petitioner asserts that: (a) Edwards 2002 discloses treating patients with RA by administering two 1,000 mg infusions of rituximab, while alleging that those patients included

inadequate responders to a TNF α -inhibitor, *id.* at 34, 36, and (b) Curd teaches the combination of rituximab with agents such as methotrexate and corticosteroids, *id.* at 52.

Petitioner also relies on Tuscano in substantially the same manner set forth in Celltrion's petition. For example, Petitioner asserts that Tuscano discloses treating RA patients with rituximab when they have not responded adequately to a TNF α -inhibitor with rituximab. *Id.* at 33. As in the Celltrion petition, Petitioner addresses the higher dose of rituximab used in Tuscano than in Edwards 2002 by asserting that a person of skill in the art would have been motivated to use the dosing regimen in Edwards 2002 in other patients because of the success achieved in Edwards 2002. *Id.* at 39.

Petitioner's combination also relies, alternatively, upon Patel. Pet. 32. Patel describes Edwards 2001⁷ as treating refractory RA patients with a regimen of rituximab. Ex. 1159, 9. Patel does not disclose the dose or schedule for the regimen. *See id.* Nor does Patel describe Edwards 2001 as including any RA patients who have not responded adequately to a TNF α -inhibitor. *See id.* Patel describes De Vita 2002 as treating RA patients, including those who have not been responsive to a TNF α -inhibitor. *Id.* Patel does not disclose the dose or schedule for the regimen. *See id.* Patel reports De Vita 2002's treatment results without identifying which of those results correspond to the TNF α -inhibitor inadequate responders. *See id.* Petitioner relies upon Patel as teaching or suggesting that "those whose RA is refractory to conventional therapy (including TNF inhibitors) may

⁷ Edwards et al., *Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes*, 40 RHEUMATOLOGY 3:205–211 (2001). Ex. 1106.

respond” to B cell-ablative therapy. Pet. 33 (quoting Ex. 1159, 1985). Thus, Patel provides substantially the same teaching as Tuscano.

As in the Celltrion Petition, Petitioner asserts that a skilled artisan would have been motivated with a reasonable expectation of success to treat RA in TNF α -inhibitor inadequate responders with rituximab because those patients had already been successfully treated with rituximab in the prior art. Pet. 37. In support of that assertion, Petitioner refers to Tuscano and Patel. *Id.* (citing Exs. 1136 and 1159). Additionally, in a substantially same manner as Celltrion, Petitioner asserts that a skilled artisan would have been motivated to treat those TNF α -inhibitor inadequate responders using the dosing regimen in Edwards 2002 of two 1000 mg infusions, instead of the varied amount in four doses disclosed in Tuscano or De Vita 2002, to improve patient compliance. *Id.* at 38.

Thus, based upon our comparison of Celltrion’s challenges over Edwards 2002 and Tuscano, and over Goldenberg, Curd, and DeVita 2001, with Petitioner’s challenge over Edwards 2002, Curd, and Tuscano or Patel, it is readily apparent that Petitioner’s cited references are the same or substantially the same as those presented in the earlier Celltrion proceeding. Moreover, our comparison of the challenges reveals that the arguments presented in the Petition are the same or substantially the same as those raised by Celltrion, i.e., absent a teaching in the prior art to treat a patient who experiences an inadequate response to a TNF α -inhibitor with rituximab administered as two intravenous doses of 1000 mg, a person of skill in the art would allegedly be motivated to treat those patients with the dosing schedule in Edwards 2002 because rituximab had been used to treat such patients, as taught by Tuscano and Patel, and a person of skill in the art

would have expected the reduced dosing schedule in Edwards 2002 to improve patient compliance. Because we have already considered substantially the same prior art and substantially the same arguments in the Celltrion proceeding, we decline to do so again.

III. CONCLUSION

For the foregoing reasons, we exercise our discretion under § 325(d) and deny the Petition.

ORDER

Accordingly, it is hereby:

ORDERED that Petitioner's request for an *inter partes* review of claims 1–14 of the '838 patent is *denied*.

PETITIONER:

Siegmund Gutman
Colin Cabral
Graham Cole
PROSKAUER ROSE LLP
sgutmanptabmatters@proskauer.com
ccabral@proskauer.com
gcole@proskauer.com

PATENT OWNER:

J. Steven Baughman
Megan Raymond
PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
sbaughman@paulweiss.com
mraymond@paulweiss.com

Michael R. Fleming
Gary N. Frischling
Keith A. Orso

IPR2017-02042
Patent 7,976,838 B2

Yite John Lu
IRELL & MANELLA LLP
mfleming@irell.com
gfrischling@irell.com
korso@irell.com
yjlu@irell.com